Clinical Trials Browser

Terminated × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × nilotinib × Clear all

NCT01751425 2025-06-03

Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors

Phase 1 Terminated

8 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Neoplasm, Residual

NCT02627677 2021-11-26

OPTIC-2L

Phase 3 Terminated

44 enrolled 22 charts

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00644878 2021-08-18

MACS0254

Phase 2 Terminated

18 enrolled 12 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02115386 2019-12-10

MACS1532

Phase 3 Terminated

7 enrolled 4 charts

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02174445 2019-12-02

DECLINE

Phase 3 Terminated

14 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02709083 2018-11-02

Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia

Phase 2 Terminated

7 enrolled 5 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02108951 2017-10-27

ENESTswift

Phase 3 Terminated

20 enrolled 17 charts

MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02086487 2017-03-07

NISRI

Phase 4 Terminated

98 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00519090 2011-11-07

ENEST

Phase 3 Terminated

6 enrolled 6 charts

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms